Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    A221701
Previous Study | Return to List | Next Study

Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer (MIST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03839940
Recruitment Status : Suspended (New drug distribution process)
First Posted : February 15, 2019
Last Update Posted : July 24, 2020
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology

Tracking Information
First Submitted Date  ICMJE February 6, 2019
First Posted Date  ICMJE February 15, 2019
Last Update Posted Date July 24, 2020
Actual Study Start Date  ICMJE February 15, 2019
Estimated Primary Completion Date February 1, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 12, 2019)
  • Incidence rate of the mTOR inhibitor-associated stomatitis (mIAS)-related pain based on daily self-reports via the numerical analogue scale [ Time Frame: Up to 8 weeks ]
    The numerical analogue mouth pain score (NAMPS) is a single item measured on a 0 to 10 scale, with 0 corresponding to "No pain" and 10 corresponding to "Pain as bad as it can be." Will compare the incidence rate of any mouth pain (i.e., any score greater than 0) as assessed by the NAMPS between the prevention versus early treatment approaches using a Chi-square test.
  • Severity of mouth pain scores [ Time Frame: Up to 8 weeks ]
    Average Area Under the Curve per assessment (aAUCpa) of mouth pain scores as measured by NAMPS will be computed for each patient to summarize the sequence of numerical analogue mouth pain scores over the eight week study period. Scores are reported on a 0-100 scale, where 100 = better outcome QOL (i.e. less pain). The aAUCpa is the average of each AUC between each sequential assessment from treatment-initiation to the end of the treatment at 8 weeks post-treatment-initiation and will be compared between the two treatment arms.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 12, 2019)
  • Incidence of grade > 2 mIAS as measured by the SWISH trial [ Time Frame: Up to 8 weeks ]
    Grade > 2 mIAS is defined as having at least one of the following criteria:
    1. Oral intake assessed at <50 on the Normalcy of Diet Scale
    2. Patient's reported oral pain (using visual analogue scale 0-10) that meets one of the following:
    rating of 7 on two consecutive days rating of 8, 9, or 10 on any one day The incidence of > grade 2 mIAS for each treatment arm will be compared by a Chi-square test.
  • Incidence of mouth pain [ Time Frame: Up to 8 weeks ]
    Will determine if the initiation of dexamethasone at the start of everolimus is associated with the incidence and of mild (score of 1-3), moderate (score of 4-6) and severe (score of 7-10) mouth pain as measured by the NAMPS. Will be assessed by Chi-square tests
  • Time to development of mouth pain [ Time Frame: Up to 8 weeks ]
    Will deterimine if the initiation of dexamethasone at the start of everolimus is associated with the time to development of mild (score of 1-3), moderate (score of 4-6) and severe (score of 7-10) mouth pain as measured by the NAMPS. Will be assessed by Kaplan-Meier and cumulative incidence curves.
  • Quality of life assessed by Linear Analogue Self-Assessment [ Time Frame: Up to 8 weeks ]
    Will determine if the initiation of dexamethasone at the start of everolimus is associated with quality of life is by comparing numerical analogue scale scores as measured by the Linear Analogue Self-Assessment. The Linear Analogue Self Assessment for quality of life is measured on a 0 to 10 scale, with 0 corresponding to "Quality of life as bad as it can be" and 10 corresponding to "Quality of life as good as it can be." Will be assessed by Independent samples t-tests.
  • Mouth/throat sore level of activity interference with daily activities [ Time Frame: Up to 8 weeks ]
    Will determine if the initiation of dexamethasone at the start of everolimus is associated with the level of interference with daily activities as measured by the Patient Reported Outcome (PRO) Common Terminology criteria for Adverse Events (CTCAE) mouth/throat item regarding level of interference with daily activities. The PRO-CTCAE mouth/throat item regarding level of interference with daily activities is measured on a Likert 1-5 scale, with 1 corresponding to "Not at all" and 5 corresponding to "Very much." Will be assessed by independent samples t-tests.
  • Sleep level of activity interference with daily activities [ Time Frame: Up to 8 weeks ]
    Will determine if the initiation of dexamethasone at the start of everolimus is associated with the level of interference with daily activities as measured by the PRO-CTCAE sleep item regarding level of interference with daily activities. The PRO-CTCAE sleep item regarding level of interference with daily activities is measured on a Likert 1-5 scale, with 1 corresponding to "Not at all" and 5 corresponding to "Very much." Will be assessed by independent samples t-tests.
  • Adherence to everolimus therapy dose [ Time Frame: Up to 8 weeks ]
    Will compare mean daily dose of everolimus between the arms. The mean daily dose of everolimus over 8 weeks will be compared between study arms using independent samples t-tests.
  • Incidence of patients stopping everolimus early [ Time Frame: Up to 8 weeks ]
    Will compare the number of patients who stopped everolimus early between the treatment arms. Will be compared using Chi-squared tests.
  • Incidence of patients reducing everolimus dose [ Time Frame: Up to 8 weeks ]
    Will compare the number of patients who reduced their everolimus dose between the treatment arms. Will be compared using Chi-squared tests.
  • Dexamethasone prescription fill rates [ Time Frame: Up to 8 weeks ]
    Will compare dexamethasone prescription fill rates between the treatment groups. This will be compared using Chi-squared tests.
  • Time to dexamethasone prescription fill [ Time Frame: Up to 8 weeks ]
    Will compare the time to dexamethasone prescription fill between the treatment groups. This will be compared using Kaplan-Meier and cumulative incidence curves.
  • Time to develop mouth sores per study arm assessed by PRO-CTCAE Mouth/throat sore item regarding severity [ Time Frame: Up to 8 weeks ]
    The time to develop at least mild, moderate or severe (including "Very severe" mouth sores per study arm as measured by the PRO-CTCAE mouth-throat sore item regarding severity. The PRO-CTCAE mouth-throat sore item regarding severity is measured on a Likert 1-5 scale, with 1 corresponding to "None" and 5 corresponding to "Very severe. Will be assessed by Kaplan-Meier and cumulative incidence curves.
  • Mean and median degrees of patient-reported mouth sores per study arm assessed by NAMPS [ Time Frame: Up to 8 weeks ]
    The mean degrees of patient-reported mouth sores per study arm as measured by the NAMPS will be assessed by independent samples t-tests.
  • Median degree of patient-reported mouth sores per study arm assessed by NAMPS [ Time Frame: Up to 8 weeks ]
    The median degrees of patient-reported mouth sores per study arm as measured by the NAMPS will be assessed by independent samples t-tests.
  • Proportion of patients who experience grade 2 stomatitis [ Time Frame: Up to 2 months ]
    The proportion of patients who experience clinician-reported grade 2 stomatitis (as measured by the CTCAE and performed at 1 and 2 months post-baseline) per study arm will be assessed by Chi-squared tests.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
Official Title  ICMJE Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)
Brief Summary This phase III trial studies how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients.
Detailed Description

PRIMARY OBJECTIVES:

I. To determine if the initiation of dexamethasone at the start of everolimus treatment prevents mTOR inhibitor-associated stomatitis (mIAS)-associated pain, compared to the initiation of placebo.

II. To determine if the initiation of dexamethasone at the start of everolimus treatment will be superior compared to the initiation of placebo in terms of the overall severity of mIAS-associated pain.

SECONDARY OBJECTIVES:

I. To utilize the same measurement method that was reported in the SWISH trial: A combination of a patient reported pain scale, data from a normalcy of diet questionnaire, and clinician grading of stomatitis to determine the incidence of > grade 2 mIAS.

II. To determine if the initiation of dexamethasone at the start of everolimus increases time to development of mouth pain using daily numerical analog scale patient-reported data collection.

III. To assess if quality of life is better when dexamethasone mouth rinse use starts at the same time as everolimus use versus at the time when mouth pain begins.

IV. To investigate if starting dexamethasone mouth rinse concurrent with starting everolimus improves patients' ability to adhere to everolimus therapy.

V. To compare dexamethasone prescription fill rates and timing between patients who received placebo versus study drug at the initiation of everolimus.

Trial Design:

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients receive everolimus orally (PO) once daily (QD) as standard of care and dexamethasone as mouthwash over 2 minutes 4 times per day (QID) for 8 weeks.

GROUP II: Patients receive everolimus PO QD as standard of care and placebo as mouthwash over 2 minutes QID for 8 weeks.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Condition  ICMJE Malignant Neoplasm
Intervention  ICMJE
  • Drug: Dexamethasone
    Given as mouthwash
  • Other: Placebo
    Given as mouthwash
  • Other: Questionnaire
    Ancillary studies
  • Other: Quality-of-Life Assessment
    Ancillary studies
  • Drug: Everolimus
    Standard of care
Study Arms  ICMJE
  • Experimental: Group I (dexamethasone)
    Patients receive 10mg oral everolimus daily as standard of care and 10ml dexamethasone oral mouthwash, swished for 2-minutes daily, for 8 weeks.
    Interventions:
    • Drug: Dexamethasone
    • Other: Questionnaire
    • Other: Quality-of-Life Assessment
    • Drug: Everolimus
  • Placebo Comparator: Group II (placebo)
    Patients receive 10mg oral everolimus daily as standard of care and 10ml placebo oral mouthwash, swished for 2-minutes daily, for 8 weeks.
    Interventions:
    • Other: Placebo
    • Other: Questionnaire
    • Other: Quality-of-Life Assessment
    • Drug: Everolimus
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Suspended
Estimated Enrollment  ICMJE
 (submitted: February 12, 2019)
279
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 2022
Estimated Primary Completion Date February 1, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Current cancer diagnosis, about to receive oral everolimus 10 mg/day with or without an endocrine agent. Patients about to receive everolimus for off label use for any cancer are also eligible.
  • Not currently receiving chemotherapy or any other agent known to cause mucositis or stomatitis. Trastuzumab and ovarian function suppression are allowed.
  • Any prior chemotherapy or other stomatitis/mucositis-causing therapy must be completed at least 2 weeks prior to registration.
  • Not currently suffering from stomatitis/mucositis or mouth ulcers. Patients should not have had any stomatitis or mouth pain for at least 7 days prior to registration.
  • Patients should not receive any other agent which would be considered treatment for stomatitis or impact the primary endpoint.
  • No history of candida infection (thrush) within the last 3 months.
  • Not currently being treated with corticosteroids.
  • No uncontrolled diabetes mellitus, defined by hemoglobin A1C greater than 8%, although A1C is not needed for all patients, hemoglobin (Hgb)A1C < 8 is required for everyone with diabetes or suspected diabetes.
  • Patients must be able to read and comprehend English. Local translation, including verbal translation of professionals (PROs) is not permitted.
  • Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03839940
Other Study ID Numbers  ICMJE A221701
NCI-2018-02648 ( Registry Identifier: NCI Clinical Trial Reporting Program )
UG1CA189823 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Alliance for Clinical Trials in Oncology
Study Sponsor  ICMJE Alliance for Clinical Trials in Oncology
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Study Chair: Kathryn Ruddy, MD Mayo Clinic
PRS Account Alliance for Clinical Trials in Oncology
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP